Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
LOS ANGELES, Aug. 28, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Ocular shares during the Class Period should contact the firm before the September 5, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that these manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information reached the public, shares of Ocular lowered in value materially, which caused investors harm according to the lawsuit.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
